LyP-1 TFA是一种具有肿瘤靶向能力的环状九肽。
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
LyP-1 TFA is a cyclic nonapeptide with tumor-targeting capability[1-2]. LyP-1 TFA can be used in research related to tumor-targeted therapy and molecular imaging[3-4].
In vitro, MDA-MB-435 human breast carcinoma cells were incubated with LyP-1 TFA (5-500µM) for 24-72 hours. LyP-1 TFA induced cell lysis and death in MDA-MB-435 cells in a dose-dependent manner. C8161 human melanoma cells were not affected by the peptide[5].
In vivo, nude mice bearing MDA-MB-435 or MDA-MB-435/VEGF-C tumors were treated with LyP-1 TFA (60µg; intravenous injection) twice a week for 4-5 weeks starting from when the tumors were palpable. LyP-1 TFA significantly inhibited tumor growth, while also inducing tumor cell apoptosis and reducing intratumoral lymphatic vessel density[5]. ApoE knockout mice were treated with LyP-1 TFA (200µg/day; intravenous injection) for 2-8 weeks. LyP-1 TFA significantly reduced the atherosclerotic plaque area induced by a high-fat diet and arterial ligation, exerting its anti-atherosclerotic effect by increasing apoptosis of macrophages within the plaques[6].
References:
[1] Zhang F, Niu G, Lin X, et al. Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids. 2012 Jun;42(6):2343-51.
[2] Song N, Zhao L, Zhu M, et al. Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv. 2019 Dec;26(1):363-375.
[3] Lin QJ, Xie ZB, Gao Y, et al. LyP-1-fMWNTs enhanced targeted delivery of MBD1siRNA to pancreatic cancer cells. J Cell Mol Med. 2020 Mar;24(5):2891-2900.
[4] Song N, Zhao L, Xu X, et al. LyP-1-Modified Multifunctional Dendrimers for Targeted Antitumor and Antimetastasis Therapy. ACS Appl Mater Interfaces. 2020 Mar 18;12(11):12395-12406.
[5] Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9381-6.
[6] She ZG, Hamzah J, Kotamraju VR, et al. Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque. J Control Release. 2016 Sep 28;238:212-220.
LyP-1 TFA是一种具有肿瘤靶向能力的环状九肽[1-2]。LyP-1 TFA可用于肿瘤靶向治疗和分子成像的相关研究[3-4]。
在体外，LyP-1 TFA（5-500μM）孵育MDA-MB-435人乳腺癌癌细胞24-72小时。LyP-1 TFA以剂量依赖方式诱导MDA-MB-435发生细胞裂解与死亡。而C8161人黑色素瘤细胞则不受该肽的影响[5]。
在体内，LyP-1 TFA（60μg；静脉注射）经静脉注射处理携带MDA-MB-435或MDA-MB-435/VEGF-C肿瘤的裸鼠，每周两次，从肿瘤可触及后开始持续4-5周。LyP-1 TFA显著抑制了肿瘤生长，同时诱导了肿瘤细胞凋亡并减少了肿瘤内淋巴管数量[5]。LyP-1 TFA（200μg/天）经静脉注射处理ApoE基因敲除小鼠2-8周。LyP-1 TFA可显著减少由高脂饮食及动脉结扎诱导的动脉粥样硬化斑块面积，同时通过增加斑块内巨噬细胞的凋亡来发挥其抗动脉粥样硬化作用[6]。
| Cell experiment [1]: | |
Cell lines | MDA-MB-435 human breast carcinoma cells, C8161 human melanoma cells |
Preparation Method | MDA-MB-435 and C8161 cells were maintained in DMEM supplemented with 10% FCS. Cells were plated, allowed to attach overnight, and then incubated with unlabeled LyP-1 TFA (5-500μM; 24-72h). |
Reaction Conditions | 5-500μM; 24-72h. |
Applications | LyP-1 TFA induced a concentration-dependent cell lysis and death specifically in MDA-MB-435 cells which bind and internalize the peptide. C8161 cells were unaffected by the peptide. |
| Animal experiment [2]: | |
Animal models | ApoE null mice (with a C57BL/6 genetic background) |
Preparation Method | Atherosclerosis was induced in mice by high-fat diet (HFD) feeding starting at 8 weeks of age. In accelerated models, complete or partial ligation of the left common carotid artery was performed. Mice were treated with LyP-1 TFA (200μg/mouse/day) via daily intravenous injections. |
Dosage form | 200μg/mouse/day; i.v.; 2-8 weeks. |
Applications | LyP-1 TFA treatment significantly reduced atherosclerotic plaque area in carotid arteries induced by arterial ligation. LyP-1 TFA also triggered apoptosis of plaque macrophages without increasing the necrotic core of plaques or causing detectable systemic side effects. |
References: | |
| Cas No. | SDF | ||
| 分子式 | C38H66F3N17O14S2 | 分子量 | 1106.16 |
| 溶解度 | 储存条件 | -20°C, away from moisture | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 904 μL | 4.5201 mL | 9.0403 mL |
| 5 mM | 180.8 μL | 904 μL | 1.8081 mL |
| 10 mM | 90.4 μL | 452 μL | 904 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet